Jan 17, 2025 · DATROWAY ® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, …

Jan 20, 2025 · Datroway works by the mAb section binding to TROP2 proteins on cancer cells, it then passes into the cells where the anticancer small molecule (DXd) is released, causing the …

DATROWAY® is for adults with unresectable or metastatic, HR+/HER2− (IHC 0, IHC 1+, or IHC 2+/ISH−) breast cancer who have received prior endocrine-based therapy and chemotherapy …

On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor …

Jan 17, 2025 · DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, …

Jan 21, 2025 · Datroway may cause eye problems, and some of these may be serious. Problems can include dry eye , pink eye ( conjunctivitis ), inflammation of the cornea ( keratitis ) or …

DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, …

1 day ago · The FDA has approved Datroway (datopotamab deruxtecan-dlnk) for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer after progression on …

Jan 17, 2025 · Datroway is comprised of a humanised anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of …

Dec 27, 2024 · DATROWAY is the first ever TROP-2 directed medicine to be approved in Japan for HR positive, HER2 negative breast cancer and is the second DXd antibody drug conjugate …